Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial
-
Altmetric Citations
Nelson, Mark; Abhayaratna, Walter; Grimm, R.; ASPREE Investigator Group; Pressman, G.; Margolis, K.; Volpi, E.; McNeil, John J.; Reid, Christopher M.; Nelson, M. R.; Stocks, Nigel; Ames, D.; Beilin, Lawrence J.
Description
Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. ASPREE will examine whether the potential primary prevention benefits of low dose aspirin outweigh the risks in older healthy individuals. Our primary hypothesis is that daily oral 100. mg enteric-coated aspirin will extend a composite primary endpoint termed 'disability-free life' including onset of dementia, total mortality, or persistent...[Show more]
dc.contributor.author | Nelson, Mark | |
---|---|---|
dc.contributor.author | Abhayaratna, Walter | |
dc.contributor.author | Grimm, R. | |
dc.contributor.author | ASPREE Investigator Group | |
dc.contributor.author | Pressman, G. | |
dc.contributor.author | Margolis, K. | |
dc.contributor.author | Volpi, E. | |
dc.contributor.author | McNeil, John J. | |
dc.contributor.author | Reid, Christopher M. | |
dc.contributor.author | Nelson, M. R. | |
dc.contributor.author | Stocks, Nigel | |
dc.contributor.author | Ames, D. | |
dc.contributor.author | Beilin, Lawrence J. | |
dc.date.accessioned | 2015-12-10T22:25:14Z | |
dc.identifier.issn | 1551-7144 | |
dc.identifier.uri | http://hdl.handle.net/1885/53388 | |
dc.description.abstract | Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. ASPREE will examine whether the potential primary prevention benefits of low dose aspirin outweigh the risks in older healthy individuals. Our primary hypothesis is that daily oral 100. mg enteric-coated aspirin will extend a composite primary endpoint termed 'disability-free life' including onset of dementia, total mortality, or persistent disability in at least one of the Katz Activities of Daily Living in 19,000 healthy participants aged 65. years and above ('US minorities') and 70. years and above (non-'US minorities'). ASPREE is a double-blind, randomized, placebo-controlled trial of oral 100. mg enteric-coated acetyl salicylic acid (ASA) or matching placebo being conducted in Australian and US community settings on individuals free of dementia, disability and cardiovascular disease (CVD) events. Secondary endpoints are all-cause and cause specific mortality, fatal and non-fatal cardiovascular events, fatal and non-fatal cancer (excluding non-melanoma skin cancer), dementia, mild cognitive impairment, depression, physical disability, and clinically significant bleeding. To 20 September 2013 14,383 participants have been recruited. Recruitment and study completion are anticipated in July 2014 and December 2018 respectively. In contrast to other aspirin trials that have largely focused on cardiovascular endpoints, ASPREE has a unique composite primary endpoint to better capture the overall risk and benefit of aspirin to extend healthy independent lifespan in older adults in the US and Australia. | |
dc.publisher | Elsevier BV | |
dc.source | Contemporary Clinical Trials | |
dc.title | Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial | |
dc.type | Journal article | |
local.description.notes | Imported from ARIES | |
local.identifier.citationvolume | 36 | |
dc.date.issued | 2013 | |
local.identifier.absfor | 110201 - Cardiology (incl. Cardiovascular Diseases) | |
local.identifier.ariespublication | u4971216xPUB272 | |
local.type.status | Published Version | |
local.contributor.affiliation | Nelson, Mark, University of Tasmania | |
local.contributor.affiliation | Abhayaratna, Walter, College of Medicine, Biology and Environment, ANU | |
local.contributor.affiliation | Grimm , R, Berman Center for Outcomes and Clinical Research | |
local.contributor.affiliation | ASPREE Investigator Group, _, Menzies Research Institute, University of Tasmania | |
local.contributor.affiliation | Pressman, G., Albert Einstein Medical Center Philadelphia | |
local.contributor.affiliation | Margolis, K., Cardiovascular Research Network Hub | |
local.contributor.affiliation | Volpi, E., University of Texas | |
local.contributor.affiliation | McNeil, John J, Monash University | |
local.contributor.affiliation | Reid, Christopher M, Monash University | |
local.contributor.affiliation | Nelson, MR., University of Tasmania | |
local.contributor.affiliation | Stocks, N., University of Adelaide | |
local.contributor.affiliation | Ames, D, University of Melbourne | |
local.contributor.affiliation | Beilin, Lawrence J., University of Western Australia | |
local.description.embargo | 2037-12-31 | |
local.bibliographicCitation.issue | 2 | |
local.bibliographicCitation.startpage | 555 | |
local.bibliographicCitation.lastpage | 564 | |
local.identifier.doi | 10.1016/j.cct.2013.09.014 | |
dc.date.updated | 2015-12-09T09:22:14Z | |
local.identifier.scopusID | 2-s2.0-84887370094 | |
local.identifier.thomsonID | 000329265300025 | |
Collections | ANU Research Publications |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Nelson_Study_design_of_ASPirin_in_2013.pdf | 276.7 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator